For years, many women entering menopause or postmenopause were told that declining sexual desire was simply part of aging. Now, a major FDA decision is changing that conversation after Addyi, often called the “pink pill,” received expanded approval for women under 65, including postmenopausal women. The drug, known generically as flibanserin, was originally approved in 2015 only for premenopausal women with hypoactive sexual desire disorder, or HSDD. The updated Addyi approval is drawing attention because it recognizes that intimacy, desire, and sexual wellness still matter later in life. It also opens the door for more conversations between women and their healthcare providers about symptoms that are often ignored or dismissed.
